WilmerHale Advises Underwriters in TCR² Therapeutics’ IPO

WilmerHale Advises Underwriters in TCR² Therapeutics’ IPO

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the joint-book running managers in the initial public offering of 5,750,000 shares of common stock of TCR² Therapeutics Inc., reflecting the full exercise of the underwriters’ option to purchase additional shares, for aggregate gross proceeds of $86.25 million. The offering priced on February 13, 2019 at $15.00 per share and closed on February 19, 2019, and the option shares closed on February 26, 2019.

The WilmerHale team included Lisa Firenze, Scott Lunin, Emily Gainor, Sean Linnehan, Alex Dzioba, Erin Garrity, Bruce Manheim, Colleen Superko and Heidi Treiber.


Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel